mTOR kinase

Class

small molecule kinase inhibitor; binds the intracellular protein FKBP-12, forming a complex that inhibits mTOR complex 1 (mTORC1)

Pathway

mTOR is a serine-threonine kinase downstream of the PI3K/AKT pathway; inhibition reduces activity of S6K1 and 4E-BP1, downstream effectors of mTOR involved in protein synthesis and cell growth (relevant to TSC-associated seizures, where mTOR pathway hyperactivation is the disease driver).

Mechanistic target of rapamycin (mTOR) is a serine-threonine kinase that functions as a central regulator of cell growth, protein synthesis, and metabolism. It operates within the PI3K/AKT signaling pathway, integrating signals about nutrient availability, energy status, and growth factor stimulation to control whether a cell builds new proteins and grows or conserves resources. mTOR exists in two distinct multiprotein complexes; the one most relevant here, mTOR complex 1 (mTORC1), drives protein synthesis through downstream effectors such as S6K1 and 4E-BP1. A distinctive class of mTOR inhibitors, known as rapalogs, does not block the kinase directly but instead binds an intracellular protein called FKBP-12; the resulting drug-protein complex then associates with and inhibits mTORC1 selectively, largely sparing the second complex, mTORC2. This selective inhibition is therapeutically important in conditions where mTOR pathway activity is pathologically elevated, such as tuberous sclerosis complex (TSC), a genetic disorder in which loss of regulatory proteins upstream of mTOR causes chronic overactivation of this growth pathway, contributing to tumor growth and, in the nervous system, to seizure activity. By dampening mTORC1 output, this mechanism addresses a root molecular driver of disease rather than merely treating symptoms, making it relevant across oncology, transplant medicine, and certain rare genetic epilepsies.